A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer
Latest Information Update: 18 Jul 2024
At a glance
- Drugs Human papillomavirus vaccine (Primary)
- Indications Cervical cancer
- Focus Adverse reactions
- 10 Jul 2024 Planned End Date changed from 31 Dec 2024 to 31 Jan 2025.
- 10 Jul 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Dec 2024.
- 27 Jul 2023 Planned End Date changed from 1 Jan 2024 to 31 Dec 2024.